Cart
sales@molnova.com
Hepln-13
CAS No. 64369-13-7
Hepln-13( Hepln 13 | Hepln13 )
Catalog No. M24659 CAS No. 64369-13-7
Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 115 | In Stock |
|
| 10MG | 192 | In Stock |
|
| 25MG | 385 | In Stock |
|
| 50MG | 575 | In Stock |
|
| 100MG | 801 | In Stock |
|
| 500MG | 1647 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHepln-13
-
NoteResearch use only, not for human use.
-
Brief DescriptionHepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
-
DescriptionHepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
-
In VitroHepln-13 (10 μM; 2 hours; 293 cells) inhibits cleavage.Western Blot Analysis Cell Line:293 cells Concentration:10 μM Incubation Time:2 hours Result:Inhibited cleavage.
-
In VivoHepIn-13 displays dose dependent inhibition of Hepsin overexpression-relevant prostate cancer phenotypes and blocks prostate cancer metastasis.
-
SynonymsHepln 13 | Hepln13
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorhepsin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number64369-13-7
-
Formula Weight325.2
-
Molecular FormulaC17H13BrN2
-
Purity>98% (HPLC)
-
SolubilityDMSO:60 mg/mL?(184.50 mM;?Need ultrasonic)
-
SMILESBrc1ccc(C(N2)Nc3cccc4cccc2c34)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5(5):1352-1362.
molnova catalog
related products
-
Norcantharidin b
Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
-
Telisotuzumab
Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.
-
BMS-2
BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
